Migraine Treatment Market

The global Migraine Treatment Market market size was USD 3.7 billion in 2023 and calculated at USD 3.94 Billion in 2024. Market revenue is projected to reach USD 7.47 Billion by 2034, and register a 6.6% over the forecast period (2025-2034).

Premium Insights:

Growth of the global Migraine Treatment market is supported significantly by rising focus on understanding migraines and triggers, and addressing needs of sufferers, which is driven by rising prevalence of this neurological disorder worldwide. Technological advancements, innovations in Research and Development (R&D) in drugs, medications, therapeutics, and personalized approaches to treat, prevent, and manage migraine, increasing product visibility and accessibility to Over-The-Counter (OTC) pain relievers and prescription medications, and advances in nasal sprays for acute Migraine Treatment and rapid results and outcomes are also key factors supporting market revenue growth. Ongoing research into Calcitonin Gene-Related Peptide (CGRP) receptor antagonist nasal spray targeting therapies for migraine prevention, is also expected to have major impact on growth of the Migraine Treatment market. Increasing number of individuals opting for preventive treatment with the intention to reduce frequency of headaches and attacks as well as severity of occurrences, and also to enable higher response and efficacy to abortive therapy.

Migraine ranks as the second leading cause of disability in some developed countries, and is highest in North America. South and Central America, Europe, Asia, and Africa follow respectively in terms of prevalence ranking. Migraines and other headaches are known to cause severe debilitating symptoms, impact sufferer’s ability to perform or work, reduce productivity and focus, cause depression and influence mental health and result in behavioral changes, and impact interpersonal relationships and quality of life.

Migraine is common and affects 1 in 10 individuals globally, and is particularly prevalent in women. Migraine can be characterized as more than a typical headache, and recurring occurrences can often be life-long. Migraines can include headache of moderate or severe intensity, one-sided or behind the eye, pulsating in quality aggravated by routine physical activity, and durations can vary from hours to days.

Migraines are typically classified into two main types: migraine with aura (classic migraine) and migraine without aura (common migraine), among which migraine without aura is most prevalent. Episodes include tension-type headaches or TTH, which occur during teenage years and affect 50% more women than men; episodic TTH, which occur less than 15 days per month and affects around 15% of some populations; chronic TTH, which could be unremitting and more disabling than episodic TTH; cluster headache or CH, which is primary, brief but severe, and frequently recurring many times a day with symptoms such as pain around one eye, tearing, and redness of eye. This type is relatively less common, and affects one in 1,000 adults, and six men to each woman, and occurs in individuals in their 20s and beyond. Medication-overuse headache or MOH is also a common form of migraine and is usually a result of chronic or excessive use of medication to treat a headache. MOH may be experienced in around 5% of some populations, is a common secondary headache disorder, is oppressive, persistent and affects more women than men.

Migraines can be triggered by simple or everyday phenomena or events such as movement, light, or sound, and can bring on fatigue, nausea, irritability, vision changes, frustration, and obviously pain. Other common triggers are stress, certain foods, sleep deprivation, and hormonal changes. Migraines are known to have a strong genetic component, but specific inheritance pattern has not yet been identified. Also, while some individuals may be regular sufferers, some relatives may never be affected or experience migraines in their lifetime. Research indicates that the genetic basis of migraine is complex and onset can be influenced by more than one genetic source at various genomic locations acting in tandem with environmental factors to influence susceptibility and

No specific test is available for diagnosis of migraine, and clinical approaches are more likely to base diagnosis based on patient history and symptomatology. Some approaches however include MRI or CT scans to rule out other potential causes of headaches. Treatment for migraines can range from OTC pain relievers and prescription medications, such as triptans and CGRP inhibitors, to non-pharmacological approaches, including lifestyle changes, biofeedback, and cognitive behavioral therapy. Neuromodulation devices, more recently, are being approved as effective in primary headache management, and present low risk, and have minimal to no adverse events. However, use requires understanding of how these devices can be integrated into the therapeutic armamentarium.

Top Market Drivers and Trends:

Traction of Diagnostics and Targeted Therapies: Development of monoclonal antibodies targeting into calcitonin gene-related peptide pathways as well as neuromodulation devices recently as non-invasive treatment for migraine are some key factors expected to support revenue growth of the Migraine Treatment market over the forecast period. Technological advancements have also been resulting in development of more effective and accurate diagnostic capabilities in the healthcare sector, as well as furthering innovations in biologics and medical devices. Such advancements are allowing for more thorough and focused research into migraine pathophysiology and targeted therapies, enabling development of personalized treatments, as well as reducing frequency and severity of attacks, thereby enhancing patient outcomes.

New Prevention Drugs and Wearable Devices: Some recent developments in the global Migraine Treatment market include use of new drugs belonging to the class called calcitonin gene-related peptide (CGRP) antagonists and include Aimovig, Ajovy, Emgality, Vyepti, Nurtec ODT, and Qulipta for the prevention of migraine. Wearable devices are also being developed and launched in the market to prevent migraines. One such product cleared by the U.S. Food and Drug Administration (FDA) for migraine prevention is the HeadaTerm 2. This wearable Transcutaneous Electrical Nerve Stimulation (TENS) device is placed with an electrode on the user’s forehead and uses low-voltage electrical currents to interact with the trigeminal nerve. This device can be used daily, and is meant to prevent migraine.

Rising Prevalence and Focus on Addressing Patient Needs: Rising prevalence of migraines and footfalls at healthcare facilities to seek treatments and management of symptoms and conditions are some key factors supporting growth of the market. These factors in turn are resulting in rising focus across healthcare organizations and research institutions to develop treatments and therapeutic solutions for chronic and episodic migraines. This includes identifying triggers and developing and offering personalized treatments, which is also resulting in further exploration of advanced epidemiological studies and tools.

Diagnostics and Therapeutics Gaining Importance: Awareness regarding the negative impacts chronic migraines and attacks can have on work, performance, and economy, as well as quality of life of patients is driving reasonable focus on the importance of diagnostic and therapeutic solutions. The economic burdens and impacts are increasingly gaining recognition among employers, insurers, and governments, and favorable policies and norms are driving an incline in demand for preventive and acute care treatments. Moreover, this trend is expected to support initiatives in pharmaceutical research and development, and more specifically in biologics and neuromodulation.

R&D and AI-Driven Advancements: Advancements in technologies and medical devices and focus on patient wellness and care are also key factors supporting growth of the market. R&D of new and innovative treatment approaches and devices such as wearable neuromodulation devices, precision medicine, and machine learning-driven diagnostic tools are contributing significantly to evolving and accurate diagnosis and targeted treatment plans. Study and integration of Artificial Intelligence (AI), Machine Learning (ML), deep learning, and analytics capabilities and tools are expected to drive further breakthroughs in migraine diagnosis, analysis, triggers, treatment, and management. Such technological advancements are also supporting epidemiological studies through gathering and provision of real-time data and enabling deeper insights into patient behaviors and outcomes.

Restraining Factor Insights

High Cost and Limited Accessibility of Devices and Treatments: Advanced diagnostics tools and treatments for migraine can be relatively costly compared to more commonly treated ailments and disorders. This factor is particularly a barrier to patients in developing economies, and where budgets are constrained, healthcare infrastructure is lacking, or offerings are more generic. This is also prevalent in majority of hospitals and clinics that are more focused on catering to common and widely reported medical conditions. Also, offerings or services catering to individuals with chronic migraine may not be comprehensive or focused, and lack of appropriate diagnostic tools and apparatus, as well as skilled personnel are factors restraining market growth. Costs of advanced diagnostic tools and treatments can also limit access and affordability to specialized treatments, and this includes access to cutting-edge solutions such as neuromodulation devices, and also biologics, such as CGRP inhibitors, and others.

R&D Challenges and Variability in Treatment Responses: Research and Development (R&D) into understanding the complex pathophysiology of migraines remains complex due to the unpredictable nature of migraines, variety of triggers, and individual variability in responses to treatments. This particularly presents challenges to develop a universally-effective therapy or treatment. In addition, these challenges are slowing down progress towards development of devices or products, wherein application-specific or individual-specific outcomes can be evaluated or ascertained further.

Potential Side Effects and Limited Efficacy: Migraine sufferers are highly hesitant to explore untested or proven solutions in the market. This can be attributed to fear of potentially worsening or aggravating existing pain and symptoms. Use of drugs and treatments have potential to cause more magnified symptoms in some patients as the responses of each individual can vary significantly. Side effects are also a major concern, and may cause dizziness, nausea, or rebound headaches in individuals. Moreover, limited efficacy, though difficult to establish, can have a negative impact on preference among some individuals. These sentiments are further fortified due to a number of currently available pharmacological treatments, including triptans and certain OTC medications, causing side effects, which can discourage use and have negative impact on potential growth of the global Migraine Treatment market.

Availability of and Preference for Alternatives: Competition from alternative therapies can have a major impact on market growth. Increasing promotion and awareness regarding benefits of holistic and natural approaches, including acupuncture, lifestyle changes, and dietary adjustments, and hesitation among some individuals to opt for non-medical treatments over conventional options or pharmaceutical interventions are factors having an impact on growth of the market.

Unfavorable Reimbursement and Lack of Cover: Lack of comprehensive reimbursement framework and medical insurance cover for newer treatments such as CGRP inhibitors are key factors having an impact on wider market potential and growth. These challenges are more pronounced in regions and countries in which Migraine Treatments are not fully covered and also where cost of treatments and devices and diagnostics are significantly high. Also, treatment and devices may not be an option for weaker sections of society as out-of-pocket costs would be prohibitive for a sizable base.

Market Opportunities

Next-Generation Biologics and Neuromodulation Devices: The Migraine Treatment market is still developing on the back of technological advancements and innovations in R&D and initiatives and treatments and devices. This presents major avenues for major companies to develop innovative therapies and next-generation biologics and neuromodulation devices. These approaches will enable tapping into the patient segment, which can be significantly large and constantly expanding, who prefer non-invasive treatments and approaches to address needs. Also, expanding developments in CGRP inhibitors and wearable devices can enable companies to cater to rising demand for more personalized and effective solutions, and will cater to needs of those patients who are aware of the available and developing solutions, those seeking more personalized and effective solutions, and individuals with need for targeted migraine management solutions.

Market Expansion and Cost-Effectiveness: A number of emerging markets hold significantly high-value revenue opportunities for major companies. Some include Asia Pacific, Latin America, and parts of Africa where prevalence of migraine is high and diagnosis is low, as is the availability of focused or specialized treatments and services. Establishing strategic partnerships with regional or local healthcare providers and developing and introducing affordable versions of migraine therapies and solutions can ease access to products and treatments and enhance revenue streams.

Mergers & Acquisitions to Enhance R&D Capabilities: Engaging in strategic mergers, acquisitions, and partnerships can enhance R&D capabilities, broaden product portfolio, and enable entry into new markets. Acquisition of smaller entities possessing specialized technologies can enable development of more advanced devices and treatments, or open access to new product pipeline. Collaborations with academic institutions, biotech firms, or AI-driven health tech startups is also a lucrative avenue to leverage so as to accelerate innovation and streamline development of breakthrough therapies and devices.

Migraine Treatment Market Segmentation:

Type of Migraine:

• Migraine with Aura
• Migraine without Aura
• Chronic Migraine
• Episodic Migraine

Treatment Type:

• Acute Treatment
  • Triptans
    • Oral Triptans
    • Nasal Triptans
    • Subcutaneous Triptans
  • Ergot Alkaloids
    • Oral Ergot Alkaloids
    • Nasal Ergot Alkaloids
  • Pain Relievers
    • Over-the-Counter (OTC) Pain Relievers
    • Prescription Pain Relievers
  • CGRP Inhibitors
    • Injectable CGRP Inhibitors
    • Oral CGRP Inhibitors
• Preventive Treatment
  • Beta Blockers
    • Propranolol
    • Metoprolol
  • Antidepressants
    • Amitriptyline
    • Venlafaxine
  • Anticonvulsants
    • Topiramate
    • Valproate
  • CGRP Monoclonal Antibodies
    • Erenumab
    • Fremanezumab
• Non-Pharmacological Treatments
  • Biofeedback
  • Cognitive Behavioral Therapy
  • Lifestyle Modifications
• Neuromodulation Devices
  • Transcranial Magnetic Stimulation (TMS) Devices
  • External Trigeminal Nerve Stimulation (eTNS) Devices

Route of Administration:

• Oral
• Parenteral
• Nasal Spray
• Others

Product Type:

• Prescription
• Over-The-Counter (OTC)

Patient Demographics:

• Pediatric Population
• Adult Population
• Geriatric Population

End-Use/Application:

• Hospitals and Clinics
• Specialty Neurology Centers
• Research and Academic Institutes
• Home Care Settings

Segment Insights:

Type of Migraine:

The migraine without aura segment is expected to account for largest revenue share over the forecast period. This type affects between 70% to 80% of migraine sufferers, and diagnosis and treatment demand volumes are substantially high as a result. Also, awareness of this type and the various conditions, symptoms, and effects continues to increase, and this is driving an incline in numbers of individuals seeking medical intervention. This can also be attributed to easy access to the Internet and availability of information, reviews, patient feedback, medical journals, programs, awareness campaigns, dedicated forums, and social media platforms and channels to gain clarity and contact information and initiate progress towards seeking solutions to address the disorder. Sufferers can also access expert opinion and online appointment in real-time with medical personnel to evaluate what would have otherwise been assumed as a regular headache. In addition, rising trend of preventive healthcare and therapies as well as awareness regarding tailored treatments and increasing spending capacity of consumers are key factors expected to support revenue growth of this segment.

Treatment Type:

The acute treatment segment is expected to account for largest revenue share among the treatment type segments in the global Migraine Treatment market over the forecast period. Factors such as need for immediate symptom relief among migraine sufferers and high demand due to efficacy of over-the-counter pain relievers, triptans, and newly developed CGRP inhibitors in reducing intensity and duration of attacks are expected to drive growth of this segment. Also, awareness regarding the effectiveness of targeted acute treatments is rising among newer patients and sufferers, and this coupled with increasing availability of these therapies across retail pharmacy and prescription outlets are factors expected to drive robust growth of this segment.

Product Type:

The Over-The-Counter (OTC) segment is expected to continue to register largest revenue share among the product type segments over the forecast period. This can be attributed to ease of accessibility to effective OTC drugs and medications such as Non-steroidal Anti-Inflammatory Drugs (NSAIDs) and analgesics. This channel is also convenient for individuals seeking to address migraines and headaches without need to visit a medical center or clinic for a prescription.

Route of Administration:

Routes of administration include oral, intranasal, parenteral, subcutaneous, and intramuscular, and transdermal patches proving effective more recently. In 2023, the oral segment accounted for largest revenue share among the other route of administration segments. This can be attributed to convenience and ease, and availability of OTC oral drugs to address headaches before onset, or during. Also, this route is more discreet and cost-effective and saves time and enables individual to ascertain and medicate when and where needed.

Patient Demographics:

The adult population segment among the patient demographics segments is expected to lead in terms of revenue share and revenue growth rate over the forecast period. Prevalence of migraines among adults aged 18-50 years is high, and high likelihood of individuals in this demographic seeking medical intervention, including for pharmacological and non-pharmacological treatments, to manage migraines, is a key factor contributing to growth of this segment. Also, purchasing power among this demographic further supports this projection.

End-Use/Application:

The hospitals and clinics segment is expected to account for largest revenue share and also the fastest revenue growth rate over the forecast period. This is attributed to the comprehensive range of diagnostic, treatment, and follow-up services provided in these settings, and especially in developed and some developing economies and regions. Also, availability of advanced technologies for imaging and neurology consultations, presence of skilled medical personnel, and capability to make accurate diagnosis of migraines and provides access to the latest therapies are other factors expected to support revenue growth of this segment.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Regional Landscape:

Among the regional markets, North America Migraine Treatment market accounted for largest revenue share in 2023. Key factors such as high awareness regarding various disorders and conditions among the general public, presence of advanced healthcare infrastructure and modernized facilities and equipment, and significantly high investment in R&D initiatives in healthcare and medicine are supporting growth of the market in the region. Among the country-level markets in North America, the US Migraine Treatment market maintains dominance in terms of revenue share, as well as accounts for highest rates of migraine diagnoses and treatment. In addition, wide access to healthcare services, favorable healthcare policies and reimbursement, and strong demand for innovative treatments like CGRP inhibitors and neuromodulation devices are key factors contributing to high major revenue share of the US.

In Europe, Germany and the UK are at the forefront of migraine diagnosis and treatment, and are benefitted by well-established healthcare infrastructure, systems, and substantial investment in migraine research. Innovations and advances in this area are expected to continue to support revenue growth of the Europe Migraine Treatment market.

Rapid revenue growth rate of the Asia Pacific Migraine Treatment market is driven by high demand for migraine diagnostics and treatments in Japan and China. This high demand is supported by rising healthcare expenditure, expanding patient population, rising awareness regarding migraine as a chronic neurological disorder, and improving access to healthcare services.

Migraine Treatment Market Competitive Landscape:

Company List:

• Pfizer Inc.
• Eli Lilly and Company
• Amgen Inc.
• GlaxoSmithKline plc.
• Novartis AG
• Bayer AG
• Allergan
• Abbott
• Allodynic Therapeutics, LLC
• AbbVie
• AOBiome
• AstraZeneca
• Aurobindo Pharma USA
• Bausch Health Companies Inc.
• Biohaven Pharmaceuticals

The competitive landscape in the global Migraine Treatment market is characterized by a mix of established pharmaceutical companies, emerging biotech firms, and innovative medical device manufacturers. Major players include Amgen, AbbVie, and Eli Lilly, which are leaders in offerings of CGRP inhibitors and other migraine therapies. These companies are focusing on extensive R&D efforts to develop next-generation Migraine Treatments, enhancing product portfolios, and deploying various strategies to maintain a competitive edge.

Key strategies employed by leading companies include collaborative partnerships with research institutions or acquisition of smaller biotech firms to gain access to innovative technologies and enhance R&D capabilities. Companies are also investing in patient support programs that improve treatment adherence and patient satisfaction, ultimately driving long-term loyalty. Focusing on geographic expansion into emerging markets with rising healthcare demands also plays a crucial role in growth strategies. Tailoring products to meet regional needs and preferences are also enabling companies to effectively tap into new customer segments, strengthen market presence, and ensure sustainable revenue growth.

Recent Developments

• May 8, 2024: AbbVie announced approval by Health Canada for its QULIPTA (atogepant) for the prevention of migraine for those adults suffering from minimum of four migraine days per month. QULIPTA is the first and only oral, small-molecule Calcitonin Gene-Related Peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine. Earlier on August 17, 2023, the company announced that it had received approval from the European Commission for AQUIPTA (atogepant), and prior to this on April 17, 2023, announced securing Food and Drug Administration (FDA) approval for expanding the indication of QULIPTA (atogepant) for preventive treatment of migraine in adults.
• April 2, 2024: The Food and Drug Administration (FDA) has cleared WAT Medical’s HeadaTerm 2 as an OTC wearable Transcutaneous Electrical Nerve Stimulation (TENS) device for the prophylactic treatment of episodic migraine in patients 18 years of age and older. The rechargeable device adheres to the forehead of the user and releases targeted electrical impulses and acts on the supraorbital nerve and supratrochlear nerve, which is the nerves that transmit migraine pain. The design is simple and is controlled with a single button. Also, the HeadaTerm 2 is one of the only wearable anti-migraine devices available without a prescription in the US.

Frequently Asked Questions:

Q: What is the global Migraine Treatment market size in 2023 and what is the projection for 2034?

A: The global Migraine Treatment market size was USD 3.7 billion in 2023 and expected to reach USD 7.47 billion in 2034.

Which regional market accounted for largest revenue share in 2023, and what is the expected trend over the forecast period?

A: North America accounted for largest revenue share in 2023, and is expected to continue to maintain its lead over the forecast period.

Q: Which are the major companies are included in the global Migraine Treatment market report?

A: Major companies in the market report are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, Allergan, Abbott, Allodynic Therapeutics, LLC, AbbVie, AOBiome, AstraZeneca, Aurobindo Pharma USA, Bausch Health Companies Inc., Biohaven Pharmaceuticals

Q: What is the projected revenue CAGR of the global Migraine Treatment market over the forecast period?

A: The global Migraine Treatment market is expected to register a CAGR of 6.6% between 2025 and 2034.

Q: What are some key factors driving revenue growth of the Migraine Treatment market?

A: Some key factors driving market revenue growth include rising prevalence of migraines worldwide, advancements in medications to treat this disorder, easy accessibility to OTC pain relievers and prescription medications, advances in nasal sprays for acute Migraine Treatment and rapid results, ongoing research into Calcitonin Gene-Related Peptide (CGRP).